Is this your company? Get featured or correct your listing →
Recent changes
- Aug 9, 2026Aug 9, 2026BillionToOne's Selloff Is a Warning for Biotech IPOs Pulse story
Investors
Latest Pulse
- Sep 22, 2026This Fall's Biotech IPOs Are Splitting Into Pops And DropsRecent biotech IPO debuts have split sharply: Parabilis Medicines popped 66.75% and BillionToOne jumped 66.67% on debut, while Electra Therapeutics closed down nearly 12% this week -- a mixed signal inside one reopened window.→
- Sep 21, 2026Electra Therapeutics Closes First Day Down 12%Electra Therapeutics priced its upsized IPO at $15 a share for roughly $350 million, then closed its first trading day on Nasdaq down nearly 12% at $13.25 -- a rockier debut than the biotech IPO market's recent run of first-day pops.→
- Aug 9, 2026Caris Leads a Wild Week for Recent IPO StocksCaris Life Sciences jumped 21.6% on a beat-and-raise quarter while BillionToOne fell 29.8% despite beating estimates, the sharpest split in the Renaissance IPO Index in weeks.→
- Aug 9, 2026BillionToOne's Selloff Is a Warning for Biotech IPOsBillionToOne beat Q2 estimates by a wide margin and still fell nearly 30% because it reiterated rather than raised guidance -- a signal about how little room newly public companies have left to disappoint.→
Coverage Timeline
newest firstAll Coverage
IPO
This Fall's Biotech IPOs Are Splitting Into Pops And Drops
Recent biotech IPO debuts have split sharply: Parabilis Medicines popped 66.75% and BillionToOne jumped 66.67% on debut, while Electra Therapeutics closed down nearly 12% this week -- a mixed signal inside one reopened window.
BY THE NUMBERS
Caris Leads a Wild Week for Recent IPO Stocks
IPO
Caris Leads a Wild Week for Recent IPO Stocks
Caris Life Sciences jumped 21.6% on a beat-and-raise quarter while BillionToOne fell 29.8% despite beating estimates, the sharpest split in the Renaissance IPO Index in weeks.
BRIEF
BillionToOne's Selloff Is a Warning for Biotech IPOs
IPO
BillionToOne's Selloff Is a Warning for Biotech IPOs
BillionToOne beat Q2 estimates by a wide margin and still fell nearly 30% because it reiterated rather than raised guidance -- a signal about how little room newly public companies have left to disappoint.
THE VC READ
Related Companies
BillionToOne FAQ
Who are BillionToOne's investors?
BillionToOne's investors include Civilization Ventures, Norwest Venture Partners.